Affiliations 

  • 1 School of Postgraduate Studies, International Medical University, 57000 Kuala Lumpur, Malaysia
  • 2 Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520
  • 3 Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520; akiko.iwasaki@yale.edu
J Immunol, 2020 Jul 15;205(2):307-312.
PMID: 32493814 DOI: 10.4049/jimmunol.2000513

Abstract

The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.